Year: 2024 | Month: February | Volume: 14 | Issue: 2 | Pages: 158-167
DOI: https://doi.org/10.52403/ijhsr.20240221
Clinical Assessment of CytoSorb® as an Adjunct Therapy in Co-morbid Patients with Meningitis Sepsis - A Case Series
Dr. Harsh Sapra1, Dr. Ila Bist2
1Senior Director & Head, Neuroanaesthesia & Neuro Critical Care, Medanta Medicity, Gurgaon
2Associate Consultant, Neuro Critical Care, Medanta Medicity, Gurgaon
Corresponding Author: Dr. Ila Bist
ABSTRACT
Objective: The aim of the case series is to provide evidence towards the effectiveness of CytoSorb® therapy in the treatment of meningitis sepsis.
Background: Meningitis sepsis affects 1.2 million people globally and results in about 0.2 million deaths each year. It is characterized by a heightened systemic inflammatory response leading to hydrocephalus, cerebral edema, infarction, and septic shock with multiorgan failure. Controlling the excessive release of cytokines and other inflammatory markers through hemoadsorption has been shown to be beneficial to patients.
Materials and Methods: In this case series, we administered CytoSorb® therapy as an adjunct rescue therapy along with antibiotics in six patients (35 to 67 years) with meningitis sepsis and other severe comorbidities.
Results: We found that CytoSorb® therapy led to hemodynamic stability, reduced mortality, and improvement in disease severity scores. Despite the diverse causes of meningitis sepsis and various comorbidities, all patients showed significant improvement in their clinical and biochemical parameters. Five of the six patients progressed towards a reduction in their treatment and an eventual recovery with no device-related adverse events.
Conclusion: Extracorporeal cytokine hemoadsorption using CytoSorb® appears to be a safe and effective therapy in the management of patients with meningitis sepsis with comorbidities.
Key words: meningitis sepsis, CytoSorb®, hemoadsorption, comorbidities, mortality, cytokine storm